Trevor Hallam
2020 - SUTRO BIOPHARMA
In 2020, Trevor Hallam earned a total compensation of $1.2M as Chief Scientific Officer at SUTRO BIOPHARMA, a 20% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $198,030 |
|---|---|
| Option Awards | $268,850 |
| Salary | $430,500 |
| Stock Awards | $211,890 |
| Other | $132,000 |
| Total | $1,241,270 |
Hallam received $430.5K in salary, accounting for 35% of the total pay in 2020.
Hallam also received $198K in non-equity incentive plan, $268.9K in option awards, $211.9K in stock awards and $132K in other compensation.
Rankings
In 2020, Trevor Hallam's compensation ranked 7,686th out of 13,090 executives tracked by ExecPay. In other words, Hallam earned more than 41.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,686 out of 13,090 | 41st |
Division Manufacturing | 3,243 out of 5,624 | 42nd |
Major group Chemicals And Allied Products | 1,311 out of 2,257 | 42nd |
Industry group Drugs | 1,135 out of 1,957 | 42nd |
Industry Biological Products, Except Diagnostic Substances | 268 out of 411 | 35th |
Source: SEC filing on April 29, 2021.
Hallam's colleagues
We found three more compensation records of executives who worked with Trevor Hallam at SUTRO BIOPHARMA in 2020.
News
SUTRO BIOPHARMA CEO William Newell's 2021 pay jumps 161% to $5.6M
April 22, 2022
SUTRO BIOPHARMA CEO William Newell's 2020 pay falls 44% to $2.2M
April 29, 2021
SUTRO BIOPHARMA CEO William Newell's 2019 pay falls 56% to $3.8M
April 24, 2020
SUTRO BIOPHARMA CEO William Newell's 2018 pay jumps 1,136% to $8.7M
April 25, 2019